Construction of a deep learning model and identification of the pivotal characteristics of FGF7- and MGST1- positive fibroblasts in heart failure post-myocardial infarction.

Journal: International journal of biological macromolecules
Published Date:

Abstract

Dysregulation of fibroblast function is closely associated with the occurrence of heart failure after myocardial infarction (post-MI HF). Myocardial fibrosis is a detrimental consequence of aberrant fibroblast activation and extracellular matrix deposition following myocardial infarction (MI). However, the heterogeneity of fibroblasts in normal cardiac tissue and heart failure tissue remains to be further investigated. We discovered that the abundance of FGF7MGST1 fibroblasts were down-regulated in post-MI HF according to scRNA-seq analysis. Key gene characteristics of FGF7MGST1 fibroblasts were uncovered through both differential expression analysis and hdWGCNA pipeline. Pseudotime analysis revealed that FGF7MGST1 fibroblasts were gradually decreased with the occurrence of heart failure. Cell-cell communication analysis indicated an enhanced secretory ability in FGF7MGST1 fibroblasts compared to other fibroblasts. Utilizing machine learning algorithms, we identified 17 feature genes of this cell population. A deep learning model capable of predicting heart failure was successfully built based on these feature genes and immune infiltration levels of post-MI HF. FGF7 was highly related to cardioprotective pathway terms, including "PI3K/AKT pathway" and "protein secretion". Parallelly, mendelian randomization analysis was adopted to better understand the causal relationships between feature genes and post-MI HF. Results indicated that MGST1 was causally associated with heart failure, consistent with single cell data. And the post-MI HF mouse model was constructed and qRT-PCR assays supported that both FGF7 and MGST1 were largely down-regulated in myocardial infarction area than other cardiac tissues. These findings provide new insights into the roles of FGF7MGST1 fibroblasts in post MI HF.

Authors

  • Xicheng Wang
    Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Xiaolan Mu
    Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200123, PR China; Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai 200335, PR China; Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai 200120, PR China.
  • Xiuhua Li
    College of Chemistry and Material and College of Physics and Energy Fujian Normal University, Fuzhou, Fujian 350108, China. Electronic address: 626725144@qq.com.
  • Chao Yang
    Translational Institute for Cancer Pain, Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences (Xinhua Hospital Chongming Branch), Shanghai 202155, P. R. China.
  • Yongchao Cai
    Key Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, PR China.
  • Changcheng Liu
    Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200123, PR China; Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai 200335, PR China; Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai 200120, PR China.
  • Zhongmin Liu
    Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200123, PR China; Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai 200335, PR China; Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai 200120, PR China. Electronic address: liu.zhongmin@tongji.edu.cn.
  • Zhiying He
    Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200123, PR China; Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai 200335, PR China; Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai 200120, PR China. Electronic address: zyhe@tongji.edu.cn.